EYEN News and Press, Eyenovia Inc. From 05/16/24

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 92.8% to $0.1153 on volume of 395,102,952 shares Crown Electrokinetics Corp. (CRKN) rose 60.2% to $0.074 on volume of 250,418,429 shares Pineapple Energy Inc. (PEGY) rose 68.4% to $0.146...

2024-05-15 17:36:35 ET More on Eyenovia Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript Eyenovia: Racing Toward The Finish Line Eyenovia Q4 2023 Earnings Preview Eyenovia falls despite FDA nod for pain therapy Seeking Alpha’s Quant Ratin...

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0....

Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the first quarter ended March 31, 2024 on ...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalm...

Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025 Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobe...

Company to demonstrate Mydcombi™ and Avenova ® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms ...

2024-03-19 12:48:26 ET More on Mid-day movers & stocks. Ontrak Health announces continuing expansion with Sentara Health Sarcos Technology and Robotics says co-founder Ben Wolff to become CEO Financial information for Aptorum Group Seeking Alpha’s ...